BG
JNP

Bellevue Group’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Bellevue Group’s Portfolio JNP Stock Details JNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-50,000
Closed -$331K – 138
2016
Q1 		$331K Buy
+50,000
New +$368K 0.06% 116

Other funds holding JNP

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bellevue Group's JNP Position: Q2 2016 in Review

Bellevue Group sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q2 2016, closing a stake of 50,000 shares — an estimated $331K sold.

Bellevue Group first reported a position in JNP in Q1 2016 and held it in 1 quarter. The position peaked at $331K in Q1 2016. 51 funds tracked by Wall St. Rank hold JNP as of Q2 2016.

  • Bellevue Group reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • Bellevue Group sold 50,000 Juniper Pharmaceuticals, Inc. Common Stock shares in Q2 2016, an estimated $331K.
  • Bellevue Group first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q1 2016 and held it in 1 quarter.
  • Bellevue Group's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $331K in Q1 2016.
  • 51 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q2 2016.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.